Tekla Capital Management LLC Allakos Inc. Transaction History

Tekla Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$76.53 - $110.43 $10.2 Million - $14.7 Million	-133,045 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$85.37 - $114.1 $2.61 Million - $3.49 Million	-30,600 Reduced 18.7%	133,045 $11.4 Million
Q1 2021 May 14, 2021	BUY	$109.73 - $153.66 $3.59 Million - $5.03 Million	32,708 Added 24.98%	163,645 $18.8 Million
Q4 2020 Feb 12, 2021	BUY	$79.58 - $152.45 $5.3 Million - $10.1 Million	66,540 Added 103.33%	130,937 $18.3 Million
Q1 2020 May 14, 2020	SELL	$44.49 - $93.39 $311,385 - $653,636	-6,999 Reduced 9.8%	64,397 $2.87 Million
Q4 2019 Feb 13, 2020	BUY	$66.49 - $137.73 $3.94 Million - $8.15 Million	59,189 Added 484.88%	71,396 $6.81 Million
Q3 2019 Nov 13, 2019	SELL	$31.0 - $89.73 $378,417 - $1.1 Million	-12,207 Reduced 50.0%	12,207 $960,000
Q1 2019 May 14, 2019	BUY	$33.79 - $51.99 $824,949 - $1.27 Million	24,414 New	24,414 $989,000

104

70.7M

43.8K

1.4K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $54.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.